NMD Pharma will also present an update on the ongoing SYNAPSE-MG Phase 2b clinical trial of ignaseclant in generalized myasthenia gravis Aarhus, Denmark, 10 March 2026 – NMD Pharma A/S, a ...
Neurodegenerative diseases rank among the most profound tragedies of the human condition, capable in various forms of robbing the afflicted of a lifetime of memories, basic comprehension, sense of ...
Boost Neuroscience is a “stealth” biotech company that has developed a proprietary synapse network platform based on the work of Nobel Laureate Dr. Thomas Südhof, M.D. Boost was spun out of Stanford ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results